Nucl Med Mol Imaging.  2011 Dec;45(4):241-247.

Alternative Medical Treatment for Radioiodine-Refractory Thyroid Cancers

Affiliations
  • 1Department of Nuclear Medicine, Seoul National University College of Medicine, 101 Daehak-ro 101Jongno-gu Seoul 110-744, Korea. jkchung@snu.ac.kr
  • 2Thyroid Center, Seoul National University Cancer Hospital, Seoul, Korea.
  • 3Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
  • 4Department of Nuclear Medicine, Seoul National University Boramae Medical Center, Seoul, Korea.

Abstract

Thyroid cancer is one of the most rapidly increasing cancers in many countries. Although most thyroid cancers are differentiated cancers and easily treated with radioiodine (RI), a portion of differentiated and undifferentiated cancers is refractory not only to RI therapy, but also to radiotherapy and chemotherapy. Thus, various alternative therapies have been tested in RI-refractory thyroid cancers. These alternative therapies include two major categories: redifferentiation therapy and recent molecular target therapy. Several clinical trials have investigated these therapies. They demonstrated potential effects of the therapies, although the results have been somewhat limited so far. Thus, the future strategy for undifferentiated thyroid cancers will involve individualized, lesion-specific, and combined therapy. In this review, the basic mechanism of each redifferentiation and molecular target therapy is discussed, and results of recent clinical trials using these therapeutic agents are summarized.

Keyword

Radioiodine-refractory; Redifferentiation; Tyrosine kinase inhibitor; Thyroid cancer

MeSH Terms

Complementary Therapies
Thyroid Gland
Thyroid Neoplasms
Full Text Links
  • NMMI
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr